深科達(688328.SH)擬以募集資金向子公司增資以實施募投項目
格隆匯3月30日丨深科達(688328.SH)公佈,公司“平板顯示器件自動化專業設備生產建設項目”和“研發中心建設項目”項目的實施主體為惠州深科達智能裝備有限公司(以下稱惠州深科達),公司擬使用“平板顯示器件自動化專業設備生產建設項目”和“研發中心建設項目”募投項目投資額1.2億元向全資子公司惠州深科達增資用於募投項目的實施,1.2億元計入惠州深科達註冊資本,新增投資額將視項目建設實際需要分期投入。增資完成後,惠州深科達的註冊資本由1,500萬元增至1.35億元,公司對惠州深科達的持股比例仍為100%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.